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polypeptide injection.
Methods: The chromatographic separation was performed using a Phenomenex Gemini C18
column (250 mm 4.6 mm, 5 mm) maintained at 30 1C. 0.1% aqueous triﬂuoroacetic acid (Solvent
A) and acetonitrile contained 0.1% TFA (Solvent B) were used as mobile phase with a gradient
elution. Detection wavelength was 280 nm with the sample injection volume of 50 mL; the ﬂow rate
was 1.0 mL/min. The ﬁngerprints of different samples were investigated by similarity analysis.
Results: Nine peaks were identiﬁed as the characteristic common peaks. The similarities of the
ﬁngerprints of the 10 batches of samples were above 0.992.
Conclusion: This method showed high precision and good repeatability, and provided the basis for
the improvement of the quality control of placenta polypeptide injection.
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om (Y. Wang).1. Introduction
Placenta has been used as a nourishing medicine since ancient
times [1]. With further research over the past several centuries, the
function of the placenta was continued to be explored in depth.
Placenta polypeptide injection, one of most widely used traditional
Chinese preparations, is made from healthy human placenta, and
mainly composed of amino acids, peptides, proteins, lipid fatty
acids and nucleic acids. With the biological activity of enhancing
cellular immune function and inhibiting peroxidation reaction,
placenta polypeptide injection can be used for the treatment of
reduction or disorder of cellular immune function, diseases caused
by surgery healing, cell infection and leucopenia. It was also
reported that placenta polypeptide injection has very good actions
in inhibiting tumors and prolonging life [2].
However, the authentic standard for the quality control of
placenta polypeptide injection was too simple to reﬂect the
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tide injection, for example, only total nitrogen item was
assigned for the assay of preparation, and furthermore, no
adequate method was used for total control of the quality of
placenta polypeptide injection.
Fingerprint technique is a powerful tool for the quality
control of multi-component herbal medicines and has been
widely accepted as a useful means for the evaluation and
quality control of herbal materials and their ﬁnished products.
Fingerprint analysis has been introduced and accepted by
World Health Organization (WHO) as a strategy for the
assessment of herbal medicines [3]. Recently, ﬁngerprint is also
required by the Drug Administration Bureau of China to
standardize injections made from traditional Chinese medi-
cines and their raw materials [4]. Cheng and Yang [5]
established a ﬁngerprint method for analyzing the quality
consistence of human placenta tissue hydrolysate of different
lots, while ﬁngerprint analysis of placenta polypeptide injec-
tion has not been reported.
The present study aimed at developing the HPLC ﬁnger-
print of placenta polypeptide injection. Then the ﬁngerprint
model could accurately reﬂect the quality and guarantee
clinical efﬁcacy of placenta polypeptide injection.2. Experimental
2.1. Materials and reagents
Acetonitrile of HPLC grade was from Fisher Scientiﬁc (NJ,
USA). Triﬂuoroacetic acid of HPLC grade was from J&K
Chemical Ltd. (Utah, USA). Other reagents were of analytical
grade. High purity water was obtained by Millipore Milli-Q
water puriﬁcation system (MA, USA). Placenta polypeptide
injection was provided by Qianfeng Biological Products Co.
(Guizhou Province, China), the speciﬁcation is 4 mL of each, the
batch numbers were 20100532, 20100953, 20100954, 20100955,
20100533, 20100578, 20100627, 20100783, 20100784 and
20100848, and are represented by 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10
below, respectively.
2.2. Instrumentation and conditions
HPLC analysis was carried out on a Shimadzu UFLC XR
HPLC equipped with binary solvent delivery pump, an auto
sampler and photodiode array detector (PAD) connected to
an LC Solution Software. The chromatographic separation
was performed using a Phenomenex Gemini C18 column
(250 mm 4.6 mm, 5 mm) maintained at 30 1C. Detection
wavelength was 280 nm with the sample injection volume of
50 mL; the ﬂow rate was 1.0 mL/min. 0.1% aqueous triﬂuor-
oacetic acid (TFA) (Solvent A) and acetonitrile contained
0.1% TFA (Solvent B) were used as mobile phase with a
gradient elution starting with 100% A, then to reach 99.5%A
and 0.5% B at 15 min and 50% A and 50% B at 35 min,
ﬁnally to reach 100% A at 36 min, and maintain 100% A at
50 min.
2.3. Sample preparation
Placenta polypeptide injection was ﬁltrated through 0.45 mm
ﬁlter before HPLC analysis.2.4. Method validation
The method validation was performed mainly on precision,
reproducibility and stability.
2.5. Obtain of HPLC ﬁngerprint and similarity analysis
To establish the representative chromatographic ﬁngerprint,
10 batches of placenta polypeptide injection were analyzed
under the established HPLC method. The obtained ﬁnger-
prints of 10 batches of placenta polypeptide injection were
analyzed automatically by professional software named Simi-
larity Evaluation System for Chromatographic Fingerprint of
Traditional Chinese Medicine composed by Chinese Pharma-
copoeia Commission (Version 2004A) (Beijing, China).3. Results and discussion
3.1. Optimization of HPLC condition
To give the most chemical information and best separation in
the chromatograms, the mobile phase and its ﬂow rate,
conditions for elution, column temperature and detection
wavelength were investigated in this study.
In the selection of mobile phase, three elution systems were
investigated. Solvent A was chosen among pure water, aqu-
eous TFA and aqueous formic acid; solvent B was acetonitrile
contained TFA. The aqueous TFA-acetonitrile contained
TFA system showed a better separation, chromatographic
peaks had moderate retention time and good resolution, so
this system was chosen to be the mobile phase. The concen-
tration of TFA in water and acetonitrile was further investi-
gated. TFA concentrations of 0.05% and 0.1% were selected
for gradient elution, the results showed that 0.1% of TFA
both in water and acetonitrile was better. The elution gradient
was also optimized and the best condition was described in
Section 2.2.
From the results of comparative study of column temperature
of 25, 30 and 35 1C and ﬂow rate of 0.8, 1.0 and 1.2 mL/min, the
ﬂow rate was set at 1.0 mL/min when column temperature was
kept at 30 1C considering resolution and running time. As we
know, peptide bond has strong UV absorption around 215 nm,
and aromatic rings have strong absorption at 280 nm, so 215 nm
and 280 nm were monitored and compared. In gradient elution,
the baseline was stable at 280 nm while ﬂuctuated with the change
in the proportion of mobile phase at 215 nm, so the detection
wavelength was ﬁnally set at 280 nm.
3.2. Method validation
In order to obtain stable and repeatable chromatographic
ﬁngerprint of placenta polypeptide injection for quality con-
trol, the method validation of HPLC ﬁngerprint analysis was
performed on the basis of the relative retention time (RRT)
and the relative peak area (RPA). Method precision was based
on replicated analysis of samples, which were injected into
HPLC system for six times. The RSDs of retention time and
peak areas of all peaks were not exceeding 1.0% and 3.0%.
The method reproducibility was studied through six-replicated
sample solutions from the same batch. The RSDs of RRT and
RPA were below 1.0% and 3.0%. The stability test was
Figure 1 The ﬁngerprints of 10 batches of placenta polypeptide injection. 1–10 represent the batches of 20100532, 20100953, 20100954,
20100955, 20100533, 20100578, 20100627, 20100783, 20100784, 20100848, respectively.
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RRT and RPA were found less than 1.0% and 3.0%,
respectively. The result indicated that the developed method
was validated and applicable for sample analysis.Figure 2 Standard ﬁngerprint of placenta polypeptide injection.
Peaks 1–9 were assigned as ‘‘characteristic common peaks’’.3.3. HPLC ﬁngerprints and similarity analysis
Under the optimal conditions, the ﬁngerprints of 10 batches of
placenta polypeptide injection were obtained (Fig. 1). It was
found that these samples had similar HPLC proﬁles.
The similarity degrees of these samples should be evaluated
by similarity analysis (SA), which has been compulsorily
carried by State Food and Drug Administration (SFDA) of
China. Using the Similarity Evaluation System for Chromato-
graphic Fingerprint of Traditional Chinese Medicine, the
representative standard ﬁngerprint was generated by the
median method (Fig. 2).
Peaks existed in the standard ﬁngerprint with reasonable
heights and good resolutions were assigned as ‘‘characteristic
common peaks’’. There were 9 characteristic peaks (from peak
1 to peak 9) in the chromatogram, which cover more than
90% of the total area. To calculate the RRT and RPA, a
reference peak should be chosen. Peak 5 had a considerably
high content of more than 30% of the total area, and it also
had moderate retention time, stable peak area and good shape.
Therefore, it was chosen as the reference peak (S). Then the
retention time and peak area of the 9 common peaks were
measured (Tables 1 and 2) and RRT and RPA of all
characteristic common peaks with respect to this reference
peak were calculated (Tables 3 and 4).
The largest variation was found in peaks 4 and 6, with both
having an RSD over 30% in RPA for the 10 batches of
samples. Considering the individual difference in humanplacenta, which is the raw materials of placenta polypeptide
injection, the concentrations of some ingredients are different
from batch to batch, especially those ingredients with low
concentration. The single peak area of peaks 4 and 6 is less
than 5% of the total area, so the two peaks’ RSD of RPA
could not be monitored, but the RRT must be controlled, in
order to guarantee the internal quality.
The similarities between the entire chromatographic proﬁles
of 10 batches of placenta polypeptide injection and the
standard chromatographic ﬁngerprint were calculated, and
the correlation coefﬁcients of their ﬁngerprints were shown as
0.992, 0.992, 0.999, 0.997, 0.997, 0.999, 0.999, 0.999, 0.999 and
1.000. These results indicated that the samples shared nearly
the same correlation coefﬁcients of similarities, showing the
internal quality of these samples was excellent.
Table 1 Retention time of 10 batches of placenta polypeptide injection.
Peak number Retention time (s)
1 2 3 4 5 6 7 8 9 10
1 5.83 5.82 5.80 5.81 5.81 5.80 5.80 5.79 5.79 5.83
2 7.21 7.18 7.16 7.16 7.15 7.14 7.14 7.12 7.12 7.21
3 8.98 8.93 8.91 8.91 8.90 8.90 8.89 8.87 8.87 8.98
4 10.07 10.00 9.98 9.98 9.97 9.96 9.95 9.94 9.93 10.07
5 (S) 11.23 11.15 11.13 11.13 11.12 11.11 11.10 11.08 11.07 11.23
6 13.38 13.30 13.29 13.27 13.27 13.24 13.25 13.23 13.20 13.38
7 23.01 22.85 22.81 22.78 22.78 22.71 22.73 22.73 22.65 23.01
8 28.68 28.68 28.68 28.67 28.67 28.66 28.65 28.64 28.65 28.68
9 32.16 32.16 32.15 32.15 32.15 32.14 32.14 32.13 32.14 32.16
Table 2 Peak area of 10 batches of placenta polypeptide injection.
Peak number Peak area
1 2 3 4 5 6 7 8 9 10
1 524,487 438,464 525,247 436,020 409,142 476,088 486,085 497,303 463,991 524,487
2 160,226 141,303 181,250 140,673 133,299 150,633 162,197 161,293 151,417 160,226
3 251,021 179,741 158,479 219,473 184,876 206,502 166,073 189,241 187,931 251,021
4 47,769 30,809 13,591 39,250 31,704 37,589 21,946 29,267 29,342 47,769
5 (S) 697,044 640,986 771,392 622,568 605,187 659,920 699,245 701,027 662,799 697,044
6 98,719 31,415 28,749 80,223 47,892 59,598 31,274 50,383 53,125 98,719
7 52,573 49,512 51,761 45,396 43,510 47,148 47,211 48,139 45,130 52,573
8 47,785 61,492 56,256 58,104 63,767 55,827 58,925 55,691 58,870 47,785
9 14,745 15,013 14,164 12,932 14,668 15,190 14,751 14,886 14,781 14,745
Table 3 Relative retention time (RRT) of 10 batches of placenta polypeptide injection.
Peak number RRT
1 2 3 4 5 6 7 8 9 10 RSD (%)
1 0.520 0.519 0.522 0.521 0.522 0.522 0.522 0.522 0.522 0.523 0.223
2 0.643 0.642 0.644 0.643 0.643 0.643 0.643 0.643 0.643 0.643 0.054
3 0.800 0.800 0.800 0.800 0.801 0.801 0.801 0.801 0.801 0.801 0.039
4 0.896 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.897 0.014
5 (S) 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0
6 1.193 1.192 1.193 1.194 1.193 1.194 1.192 1.194 1.194 1.193 0.063
7 2.048 2.049 2.049 2.049 2.047 2.049 2.045 2.048 2.052 2.047 0.098
8 2.552 2.555 2.572 2.576 2.576 2.579 2.580 2.582 2.585 2.589 0.381
9 2.860 2.865 2.884 2.888 2.889 2.892 2.894 2.896 2.900 2.904 0.398
Table 4 Relative peak area (RPA) of 10 batches of placenta polypeptide injection.
Peak number RPA
1 2 3 4 5 6 7 8 9 10 RSD (%)
1 0.683 0.752 0.684 0.681 0.700 0.676 0.721 0.695 0.709 0.700 3.375
2 0.227 0.230 0.220 0.235 0.226 0.220 0.228 0.232 0.230 0.228 2.157
3 0.366 0.360 0.280 0.205 0.353 0.305 0.313 0.238 0.270 0.284 16.824
4 0.061 0.069 0.048 0.018 0.063 0.052 0.057 0.031 0.042 0.044 32.539
5 (S) 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0
6 0.128 0.142 0.049 0.037 0.129 0.079 0.090 0.045 0.072 0.080 42.346
7 0.080 0.075 0.077 0.067 0.073 0.072 0.071 0.068 0.069 0.068 5.014
8 0.123 0.069 0.096 0.073 0.093 0.105 0.085 0.084 0.079 0.089 12.840
9 0.034 0.021 0.023 0.018 0.021 0.024 0.023 0.021 0.021 0.022 7.619
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An HPLC method was developed for ﬁngerprint of placenta
polypeptide injection. The ﬁngerprints of 10 batches of placenta
polypeptide injection were obtained and analyzed by the profes-
sional software. This method showed high precision and good
repeatability, and provided the basis for the improvement of the
quality control of placenta polypeptide injection. It is a worthy
further study to characterize the 9 common peaks.
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